ALCLS Fundamental Analysis - CELLECTIS

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ALCLS. ALCLS was compared to 71 industry peers in the Biotechnology industry. While ALCLS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALCLS is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALCLS has reported negative net income.

ALCLS had a positive operating cash flow in the past year.

In the past 5 years ALCLS always reported negative net income.

In the past 5 years ALCLS reported 4 times negative operating cash flow.

1.2 Ratios

ALCLS has a Return On Assets (-14.12%) which is comparable to the rest of the industry.

The Return On Equity of ALCLS (-41.34%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROIC	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 4.64%, ALCLS perfoms like the industry average, outperforming 46.48% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for ALCLS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	4.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALCLS has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALCLS has more shares outstanding

The debt/assets ratio for ALCLS has been reduced compared to a year ago.

2.2 Solvency

ALCLS has an Altman-Z score of -1.07. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ALCLS (-1.07) is comparable to the rest of the industry.

ALCLS has a debt to FCF ratio of 4.88. This is a neutral value as ALCLS would need 4.88 years to pay back of all of its debts.

Looking at the Debt to FCF ratio, with a value of 4.88, ALCLS belongs to the top of the industry, outperforming 83.10% of the companies in the same industry.

A Debt/Equity ratio of 0.65 indicates that ALCLS is somewhat dependend on debt financing.

ALCLS's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. ALCLS outperforms 49.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Altman-Z	-1.07

ROIC/WACCN/A

WACC6.07%

2.3 Liquidity

ALCLS has a Current Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

ALCLS has a Current ratio (1.73) which is comparable to the rest of the industry.

ALCLS has a Quick Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

ALCLS has a Quick ratio of 1.73. This is comparable to the rest of the industry: ALCLS outperforms 50.70% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.73
Quick Ratio	1.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.54% over the past year.

Looking at the last year, ALCLS shows a very strong growth in Revenue. The Revenue has grown by 357.43%.

Measured over the past years, ALCLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.44% on average per year.

EPS 1Y (TTM)45.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-325%

Revenue 1Y (TTM)357.43%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%85.12%

3.2 Future

Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.28% on average per year.

The Revenue is expected to grow by 30.02% on average over the next years. This is a very strong growth

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue Next Year63.01%

Revenue Next 2Y30.93%

Revenue Next 3Y12.51%

Revenue Next 5Y30.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALCLS is valued cheaply inside the industry as 94.37% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	7.7
EV/EBITDA	N/A

4.3 Compensation for Growth

ALCLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALCLS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTIS

EPA:ALCLS (6/6/2025, 7:00:00 PM)

1.288

-0.02 (-1.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12/amc

Earnings (Next)08-04 2025-08-04

Inst Owners20.91%

Inst Owner ChangeN/A

Ins Owners3.88%

Ins Owner ChangeN/A

Market Cap129.17M

Analysts85.71

Price Target6.63 (414.75%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)82%

Min EPS beat(2)18.3%

Max EPS beat(2)145.69%

EPS beat(4)4

Avg EPS beat(4)73.41%

Min EPS beat(4)6.42%

Max EPS beat(4)145.69%

EPS beat(8)6

Avg EPS beat(8)27.22%

EPS beat(12)9

Avg EPS beat(12)23.55%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)108.7%

Min Revenue beat(2)55.84%

Max Revenue beat(2)161.56%

Revenue beat(4)4

Avg Revenue beat(4)91.56%

Min Revenue beat(4)50.31%

Max Revenue beat(4)161.56%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)30%

EPS NQ rev (1m)0%

EPS NQ rev (3m)8.04%

EPS NY rev (1m)0%

EPS NY rev (3m)-18.27%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)19.78%

Revenue NY rev (1m)0%

Revenue NY rev (3m)46.67%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2
P/FCF	7.7
P/OCF	6.41
P/B	1.12
P/tB	1.13
EV/EBITDA	N/A

EPS(TTM)-0.53

EYN/A

EPS(NY)-0.77

Fwd EYN/A

FCF(TTM)0.17

FCFY12.99%

OCF(TTM)0.2

OCFY15.6%

SpS0.64

BVpS1.14

TBVpS1.14

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	4.64%
FCFM	25.96%

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Debt/EBITDA	N/A
Cap/Depr	19.36%
Cap/Sales	5.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.73
Quick Ratio	1.73
Altman-Z	-1.07

F-Score7

WACC6.07%

ROIC/WACCN/A

Cap/Depr(3y)12.8%

Cap/Depr(5y)139.39%

Cap/Sales(3y)9.66%

Cap/Sales(5y)33.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-325%

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue 1Y (TTM)357.43%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%85.12%

Revenue Next Year63.01%

Revenue Next 2Y30.93%

Revenue Next 3Y12.51%

Revenue Next 5Y30.02%

EBIT growth 1Y35.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-28.14%

EBIT Next 3Y-33.24%

EBIT Next 5Y-29.24%

FCF growth 1Y174.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y192.9%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens